Analyst Ratings For Editas Medicine (NASDAQ:EDIT)
Today, CLSA initiated coverage on Editas Medicine (NASDAQ:EDIT) with a Underperform.
Some recent analyst ratings include
- 2/13/2018-CLSA initiated coverage with a Underperform rating.
- 1/23/2018-SunTrust Banks Upgrade from a “Hold ” rating to a ” Buy” rating.
- 11/7/2017-Cann Reiterated Rating of Hold.
- 11/7/2017-Cowen Reiterated Rating of Buy.
- 10/6/2017-Morgan Stanley Reiterated Rating of Equal Weight.
- 9/6/2017-Barclays initiated coverage with a Overweight rating.
Recent Insider Trading Activity For Editas Medicine (NASDAQ:EDIT)
Editas Medicine (NASDAQ:EDIT) has insider ownership of 19.40% and institutional ownership of 64.52%.
- On 2/1/2018 Katrine Bosley, CEO, sold 8,333 with an average share price of $36.18 per share and the total transaction amounting to $301,487.94.
- On 1/30/2018 Katrine Bosley, Insider, sold 20,000 with an average share price of $38.79 per share and the total transaction amounting to $775,800.00.
- On 1/23/2018 Katrine Bosley, Insider, sold 3,338 with an average share price of $35.28 per share and the total transaction amounting to $117,764.64.
- On 1/3/2018 Katrine Bosley, Insider, sold 14,995 with an average share price of $34.15 per share and the total transaction amounting to $512,079.25.
- On 12/19/2017 Andrew A F Hack, CFO, sold 14,649 with an average share price of $24.68 per share and the total transaction amounting to $361,537.32.
- On 12/15/2017 Andrew A F Hack, CFO, sold 5,000 with an average share price of $24.31 per share and the total transaction amounting to $121,550.00.
- On 12/1/2017 Katrine Bosley, Insider, sold 8,333 with an average share price of $29.58 per share and the total transaction amounting to $246,490.14.
Recent Trading Activity for Editas Medicine (NASDAQ:EDIT)
Shares of Editas Medicine closed the previous trading session at 32.89 up +0.04 0.12% with 34.25 shares trading hands.
